2-氧代-3-哌啶甲酰肼 | 215778-26-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 2-氧代-3-哌啶甲酰肼
• 英文名称: 2-Oxopiperidine-3-carbohydrazide
• CAS: 215778-26-0
• 化学式: C₆H₁₁N₃O₂
• mdl: MFCD00218098
• 分子量: 157.17
• InChiKey: NYCBGDUPPBUSPC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.7
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.666
• 拓扑面积：
  84.2
• 氢给体数：
  3
• 氢受体数：
  3

文献信息

• 9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use
  申请人：Merck Sharp & Dohme Corp.

  公开号：US11312719B2

  公开（公告）日：2022-04-26

  In its many embodiments, the present invention provides certain 9-substituted amino triazolo quinazoline compounds of the structural Formula (I): and pharmaceutically acceptable salts thereof, wherein, ring A, R1 and R2 are as defined herein, pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other therapeutically active agents), and methods for their preparation and use, alone and in combination with other therapeutic agents, as antagonists of A2a and/or A2b receptors, and in the treatment of a variety of diseases, conditions, or disorders that are mediated, at least in part, by the adenosine A2a receptor and/or the adenosine A2b receptor.

  本发明在其各种实施例中，提供具有结构式 (I) 的某些 9-取代氨基三氮唑喹唑啉化合物及其药学上可接受的盐，其中，环 A、R1 和 R2 的定义如前所述。本发明还包括包含一种或多种此类化合物（单独或与其他一种或多种治疗活性剂组合）的药用组合物，以及制备和使用这些化合物的方法（单独或与其他治疗剂组合），作为 A2a 和/或 A2b �受体的拮抗剂，以及在治疗由腺苷 A2a 受体和/或腺苷 A2b 受体介导（至少部分）的各种疾病、状况或紊乱中的用途。
• 9-SUBSTITUTED AMINO TRIAZOLO QUINAZOLINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20210107904A1

  公开（公告）日：2021-04-15

  In its many embodiments, the present invention provides certain 9-substituted amino triazolo quinazoline compounds of the structural Formula (I): and pharmaceutically acceptable salts thereof, wherein, ring A, R 1 and R 2 are as defined herein, pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other therapeutically active agents), and methods for their preparation and use, alone and in combination with other therapeutic agents, as antagonists of A2a and/or A2b receptors, and in the treatment of a variety of diseases, conditions, or disorders that are mediated, at least in part, by the adenosine A2a receptor and/or the adenosine A2b receptor.